Krunoslav T. Stingl

Dr. Krunoslav T. Stingl


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2022 in British Journal of Ophthalmology
Verified
Journal Article
Closed access
PDF file
FRFelix F Reichel
Felix F Reichel
ISImmanuel Seitz
Immanuel Seitz
FWFabian Wozar
Fabian Wozar
SDSpyridon Dimopoulos
Spyridon Dimopoulos
RJRonja Jung
Ronja Jung
MFM. Dominik Fischer
M. Dominik Fischer
Background/aims: Voretigene neparvovec (VN) is the first and only subretinal gene therapy approved by the Food and Drug Administration and European Medicines Agency. Real-world application has started in 2018 in patients with vision impairment due to biallelic retinal pigment epithelium (RPE)65mutation-associated inherited retinal degenerations. Herein, we evaluated the development of retinal atrophy within in a single-centre patient cohort treated with VN.Methods: 13 eyes of eight patients treated with VN were retrospectively analysed for areas of retinal atrophy over a period of 6–24 months following surgery. Ultrawide field images were used to measure the area of atrophy. Fundus autofluorescence imaging is presented as an instrument for early detection of signs of retinal atrophy in these patients.Results: Atrophic changes beyond the retinotomy site were observed in all eyes. Areas of atrophy developed within the area of detachment (bleb) in all eight patients and outside the bleb in three patients. Changes in autofluorescence preceded the development of retinal atrophy and were already evident 2 weeks after surgery in the majority of patients. The areas of atrophy increase with time and progression continued over year 1. Functional outcomes remained stable (VA, FST, visual field).Conclusion: Subretinal injection of VN can lead to RPE atrophy with consequent photoreceptor loss in and outside of the bleb area. Fundus autofluorescence is an important tool to monitor atrophic changes in patients after gene therapy. Interestingly, while areas of atrophy also included central areas, the functional benefits of the treatment did not appear to be affected and remained stable.

21 February 2023 in Ophthalmology
Verified
Journal Article
Closed access
KSKatarina Stingl
Katarina Stingl
KSKrunoslav T. Stingl
Krunoslav T. Stingl
HSHillary Schwartz
Hillary Schwartz
MRMark W. Reid
Mark W. Reid
MKMelanie Kempf
Melanie Kempf
ANAaron Nagiel
Aaron Nagiel

1 March 2012 in NeuroImage
Verified
Journal Article
Closed access
KSKrunoslav T. Stingl
Krunoslav T. Stingl
SKStephanie Kullmann
Stephanie Kullmann
CKCaroline Ketterer
Caroline Ketterer
MHMartin Heni
Martin Heni
HHHans-Ulrich Häring
Hans-Ulrich Häring
HPHubert Preissl
Hubert Preissl

9 September 2022 in Progress in Retinal and Eye Research
Verified
Journal Article
Open access
KSKrunoslav T. Stingl
Krunoslav T. Stingl
MKMelanie Kempf
Melanie Kempf
Ronja JungRonja Jung
Ronja Jung
FKFriederike Kortüm
Friederike Kortüm
GRGiulia Righetti
Giulia Righetti
KSKatarina Stingl
Katarina Stingl
Retinal gene supplementation therapy such as the first approved one, voretigene neparvovec, delivers a functioning copy of the missing gene enabling the protein transcription in retinal cells and restore visual functions. After gene supplementation for the genetic defect, a complex network of functional regeneration is the consequence, whereas the extent is very individualized. Diagnostic and functional testings that have been used routinely by ophthalmologists so far to define the correct diagnosis, cannot be applied in the new context of defining small, sometimes subtle changes in visual functions. New view on retinal diagnostics is needed to understand this processes that define safety and efficacy of the treatment. Not only does vision have many aspects that must be addressed by specific evaluations and imaging techniques, but objective readouts of local retinal function for rods and cones separately have been an unmet need until recently. A reliable test-retest variability is necessary in rare diseases such as inherited retinal dystrophies, because statistics are often not applicable due to a low number of participants. Methods for a reliable individual evaluation of the therapy success are needed. In this manuscript we present an elaboration on retinal diagnostics combining psychophysics (eg. full-field stimulus threshold or dark adapted perimetry) as well as objective measures for local retinal function (eg. photopic and scotopic chromatic pupil campimetry) and retinal imaging for a meaningful workflow to apply in evaluation of the individual success in patients receiving gene therapy for photoreceptor diseases.

20 January 2021 in British Journal of Ophthalmology
Verified
Journal Article
Open access
PDF file
KSKrunoslav T. Stingl
Krunoslav T. Stingl
MKMelanie Kempf
Melanie Kempf
KBKarl U Bartz-Schmidt
Karl U Bartz-Schmidt
SDSpyridon Dimopoulos
Spyridon Dimopoulos
FRFelix Reichel
Felix Reichel
KSKatarina Stingl
Katarina Stingl
Background: Voretigene neparvovec is a gene therapeutic agent for treatment of retinal dystrophies caused by bi-allelic RPE65 mutations. In this study, we report on a novel and objective evaluation of a retinotopic photoreceptor rescue.Methods: Seven eyes of five patients (14, 21, 23, 24, 36 years, 1 male, 4 females) with bi-allelic RPE65 mutations have been treated with voretigene neparvovec. The clinical examinations included visual acuity testing, dark-adapted full-field stimulus threshold (FST), dark-adapted chromatic perimeter (DAC) with a 30-degree grid, and a 30 degrees grid scotopic and photopic chromatic pupil campimetry (CPC). All evaluations and spectral domain optical coherence tomography were performed at baseline, 1 month and 3 months.Results: All except the oldest patient had a measurable improvement of the rod function assessed via FST, DAC or scotopic CPC at 1 month. The visual acuity improved slightly or remained stable in all eyes. A cone function improvement as measured by photopic CPC was observed in three eyes. The gain of the dark-adapted threshold with blue FST and the DAC stimuli (cyan) average correlated strongly with age (R2>0.7). The pupil response improvement in the scotopic CPC correlated with the baseline local retinal volume (R2=0.5).Conclusions: The presented protocols allow evaluating the individual spatial and temporal effects of gene therapy effects. Additionally, we explored parameters that correlated with the success of the therapy. CPC and DAC present new and fast ways to assess functional changes in retinotopic maps of rod and cone function, measuring complementary aspects of retinal function.

21 May 2014 in Human Brain Mapping
Verified
Journal Article
Closed access
MHMaike A. Hege
Maike A. Hege
HPHubert Preissl
Hubert Preissl
KSKrunoslav T. Stingl
Krunoslav T. Stingl